Norway· NO-ID_4D4C6499-D91E-4738-B025-1B99EEC17F0C
Skyrizi
A risankizumab product containing risankizumab, registered in Norway by AbbVie Deutschland GmbH & Co. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Risankizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC18 (risankizumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Risankizumab · ATC L04AC18
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of risankizumab costs, country by country.
Normalised to the WHO defined daily dose (1.67 mg), the median price runs from $0.035 in France to $26.21 in Switzerland — a ×755 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Risankizumab · price per daily dose (1.67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$26.21
- FR France$0.035
The record
At a glance
FEST (Norway)- Active substance
- Risankizumab
- Manufacturer
- AbbVie Deutschland GmbH & Co
- Country
- Norway (NO)
- ATC code
- L04AC18
- ATC class
- Risankizumab
- Defined daily dose
- 1.67 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_4D4C6499-D91E-4738-B025-1B99EEC17F0C
- no_varenummer039302600NOK 46384.6
- gtin8054083025018
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
75 interactions on record for risankizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Risankizumab · interactions on record
75 records
- 27 severe
- 41 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Risankizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSkyriziAbbVie Deutschland GmbH&Co.KG
- CzechiaSKYRIZIAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- BelgiumSkyrizi 600 mgAbbVie Deutschland
- IcelandSkyriziAbbVie Deutschland GmbH & Co. KG
- PolandSkyriziAbbVie Deutschland GmbH & Co. KG
- SwedenSkyrizi 600 mg Koncentrat till infusionsvätska, lösningAbbVie Deutschland GmbH & Co KG
- IrelandSkyrizi 600 mg Concentrate for solution for injectionAbbVie Deutschland GmbH & Co. KG
- United StatesSkyriziAbbVie Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Skyrizi
- Iceland · Skyrizi
- Liechtenstein · Skyrizi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2e22b220-9b43-40ba-9c50-362313cc5198 GET /v1/drugs/2e22b220-9b43-40ba-9c50-362313cc5198?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Risankizumab",
"merkevare_id": "ID_4D4C6499-D91E-4738-B025-1B99EEC17F0C",
"name_form_strength": "Skyrizi kons til inf oppl 600 mg",
"prescription_group": "C"
}See everything about risankizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.